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Abstract
Background: Pharmacological interactions are useful for understanding ligand binding mechanisms of a
therapeutic target. These interactions are often inferred from a set of active compounds that were acquired
experimentally. Moreover, most docking programs loosely coupled the stages (binding-site and ligand preparations,
virtual screening, and post-screening analysis) of structure-based virtual screening (VS). An integrated VS
environment, which provides the friendly interface to seamlessly combine these VS stages and to identify the
pharmacological interactions directly from screening compounds, is valuable for drug discovery.
Results: We developed an easy-to-use graphic environment, iGEMDOCK, integrating VS stages (from preparations
to post-screening analysis). For post-screening analysis, iGEMDOCK provides biological insights by deriving the
pharmacological interactions from screening compounds without relying on the experimental data of active
compounds. The pharmacological interactions represent conserved interacting residues, which often form binding
pockets with specific physico-chemical properties, to play the essential functions of a target protein. Our
experimental results show that the pharmacological interactions derived by iGEMDOCK are often hot spots
involving in the biological functions. In addition, iGEMDOCK provides the visualizations of the protein-compound
interaction profiles and the hierarchical clustering dendrogram of the compounds for post-screening analysis.
Conclusions: We have developed iGEMDOCK to facilitate steps from preparations of target proteins and ligand libraries
toward post-screening analysis. iGEMDOCK is especially useful for post-screening analysis and inferring pharmacological
interactions from screening compounds. We believe that iGEMDOCK is useful for understanding the ligand binding
mechanisms and discovering lead compounds. iGEMDOCK is available at http://gemdock.life.nctu.edu.tw/dock/
igemdock.php.
Background
Structure-based drug design is widely used to identify
lead compounds with the growing availability of protein
structures [1-3]. Many tools (e.g., GEMDOCK [4],
DOCK [5], AutoDock [6], and GOLD [7]) have been
developed for virtual screening (VS) and successfully
identified lead compounds for some target proteins.
However, the accuracy of these docking tools remained
intensive because of the incomplete understandings of
ligand binding mechanisms [1-3]. In addition, most of
scoring functions are lack of pharmacological interac-
tions that are essential for ligand binding or biological
functions [8]. Recently, some approaches have been pro-
posed to derive pharmacological interactions from
known compounds [8-10]. These approaches apparently
increase hit rates for identifying the active compounds
which are often similar to the known compounds. In
addition, these approaches are often unable to be
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compounds.
Generally, a VS procedure consists of four main steps:
preparations of the target protein and the compound
library, docking and post-screening analysis (e.g., cluster-
ing compounds and pharmacological interactions). Most
docking programs (e.g. DOCK [5] and AutoDock [6])
only provide docked poses or loosely coupled these
steps. They often provided limit ability for post-screen-
ing analysis. Therefore, a VS framework, providing an
easy-to-use graphic and integrated environment, is an
emergent task for drug discovery.
To address these issues, we have developed a struc-
ture-based VS framework, named iGEMDOCK, from
preparations through to post-screening analysis. iGEM-
DOCK is an integrated environment, which integrates
the heavily modified and enhanced in-house tool
GEMDOCK, protein-ligand profiles, pharmacological
interactions, and compound clusters. GEMDOCK was
comparative to several docking tools (e.g. DOCK [5] and
GOLD [7]) and has been successfully applied to identify
new inhibitors and new binding sites for some targets
[4,8,11-14]. Notably, iGEMDOCK derives the pharmaco-
logical interactions from screening compounds without
using a set of known active compounds. The pharmaco-
logical interactions, which often form binding pockets
with specific physico-chemical properties of the target
protein, can represent conserved interactions between
the interacting residues and the screening compounds.
We initially validated the pharmacological interactions
on three therapeutic protein targets, including estrogen
receptor a for antagonists and agonists and thymidine
kinase. Our experimental results show that the derived
pharmacological interactions are often essential for the
ligand binding or maintaining biological functions for
these targets. In addition, iGEMDOCK provided a post-
screening analysis module, which is convenient for clus-
tering compounds and visualizing the pharmacological
interactions by interaction profiles. We believe that
iGEMDOCK is useful for drug discovery and identifying
essential residues and interactions for understanding the
binding mechanisms.
Methods
Preparations of proteins and compound sets
To initially validate the pharmacological interactions, we
selected three therapeutic protein targets, including
estrogen receptor a for agonists (ERA, PDB code 1gwr
[15]), estrogen receptor a for antagonists (ER, PDB code
3ert [16]), and thymidine kinase (TK, PDB code 1kim
[17]) because these proteins were well studied. The cata-
lytic mechanisms, biological functions, key functional
residues, and active compounds of the three targets were
available in the literatures. Estrogen receptor is an
important therapeutic target for osteoporosis and breast
cancer [18], and TK is a drug target for the therapy of
herpes simplex virus type-1 [19]. Moreover, we also eval-
uate the docking and screening accuracy of iGEMDOCK.
For docking, a highly diverse dataset comprising 305 pro-
tein-compound complexes (i.e., CCDC/Astex set [20])
was selected; for screening, we prepared 10 known active
compounds and 990 compounds were randomly selected
from Available Chemical Directory (ACD) proposed by
Bissantz et al. [21] for each therapeutic protein target.
Main procedure
iGEMDOCK is an integrated VS environment from pre-
parations through post-screening analysis with pharma-
cological interaction s( F i g .1 A ) .F i r s t ,iGEMDOCK
provides interactive interfaces to prepare both the bind-
ing site of the target protein and the screening com-
pound library (Figs. 1B and 1C). Each compound in the
library is then docked into the binding site by using the
in-house docking tool GEMDOCK [4]. Subsequently,
iGEMDOCK generates protein-compound interaction
profiles of electrostatic (E), hydrogen-bonding (H), and
van der Waals (V) interactions. Based on these profiles
and compound structures, iGEMDOCK infers the phar-
macological interactions and clusters the screening com-
pounds for the post-screening analysis (Figs. 1D and
1E). Finally, iGEMDOCK ranks and visualizes the
screening compounds by combining the pharmacologi-
cal interactions and energy-based scoring function of
GEMDOCK.
Mining pharmacological interactions
iGEMDOCK mines the pharmacological interactions
based on protein-compound interaction profiles (Fig. 2).
The size of each profile is N×2K where N and K are the
numbers of screening compounds and interacting resi-
dues of the target protein, respectively. Here, an inter-
acting residue is divided into two interacting groups:
main and side chains. A profile P(I) with type I (E, H, or
V) is given as (Fig. 2A):
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where pi,j is a binary value (0 or 1) for the compound i
interacting to the residue group j.I nt h eEa n dHp r o -
files, the pi,j is set to 1 (green) if hydrogen-bonding or
electrostatic interactions are yielded between the com-
pound i and the residue j (energy ≤ -2.5 kcal/mol);
otherwise, pi,j=0 (black). For the V profile, pi,j =1i ft h e
interacting energy is less than -4 kcal/mol (Fig. 2A).
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Figure 1 Overview of iGEMDOCK using estrogen receptor a as the example. (A) Main steps. (B) The protein-ligand docking/screening
interface. This interface provides an easy way for the preparations of binding site and screening compounds, the customization of docking
parameters, and monitoring the docking progress. (C) The binding site preparation interface in the docking/screening stage. iGEMDOCK allows
users to directly set the binding site and visualize the structure. (D) The post-screening analysis interface displays the protein-ligand complex
structures, clusters, and ranks of screening compounds. (E) The hierarchical tree presents the compound similarities using compound structures
or protein-compound interactions.
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Page 3 of 11After the generations of the profiles, we identified the
pharmacological interactions. For each interacting resi-
due group, the z-score value is used to measure the
interaction conservation between the interacting groups
and the screening compounds. For computing the z-
scores of interacting groups in a profile, 1000 randomly
shuffled profiles are utilized to obtain the standard
deviation (s)a n dm e a n( μ). The z-score of the interact-
ing residue group j is defined as Z
f
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Figure 2 Interaction profiles and pharmacological interactions. (A) Protein-compound interaction profiles of ERA. The conserved interacting
residues (B) E353 and R394 as well as (C) L525 and H524 form hydrogen bonds with the screening compounds. On average, 70% (>700) and
40% (>400) screening compounds have vdW contacts with (D) the upper hydrophobic pocket residues (L387, L391 and F404) and (E) the
bottom hydrophobic pocket residues (L346, L384, and H524), respectively. (F) 10 active compounds highly agree to form hydrogen bonds with
residues R394, E353, L525, and H524. (G) The interactions and (H) visualizations of pharmacological interactions in the post-screening analysis
interface.
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Page 4 of 11screening compounds. Finally, we normalize the z-score
value as follows:
W
z
z
j
z
z j
j
j
=
>
≤
⎧
⎨
⎪
⎩ ⎪
max        if   0 
            if   0 0
(1)
where Wj is the interaction conservation of the residue
group j related to the largest z-score (zmax) among all of
interacting groups in the binding site. Here, an interaction
conservation is viewed as a pharmacological preference
and an interaction is considered as the pharmacological
interaction if Wj ≥ 0.4. For example, for the hydrogen pro-
file of the target ERA, the pharmacological preferences of
E353 and R394 are 0.64 and 0.80, respectively; for the V
profile, the preferences of L387, L391, and F404 are 1.00,
0.61, and 0.90, respectively (Fig. 2B). In this case, over 300
(>30%) screening compounds form hydrogen bonds with
the residues E353 or R394 by polar moieties (e.g., hydroxyl
group (27%), carboxyl group (20%), sulfuric acid monoe-
ster (9%), ketone (8%), and phosphoric acid monoester
(6%)). Moreover, the aromatic rings of the screening com-
pounds are often sandwiched by vdW interacting residues
L387, L391, and F404 (Fig. 2D).
Based on the pharmacological interactions, we devel-
oped a pharmacological scoring function for identifying
the active compounds from thousands of screening com-
pounds. The pharmacological scoring function is given as
EE E E E pharma GEMDOCK pharma pharma pharma =++ + () ( ) . () EH V 20 5 (2)
where EGEMDOCK i st h ed o c k e de n e r g yo fG E M D O C K
and E(E)pharma, E(H)pharma, and E(V)pharma are the phar-
macological scores of electrostatics, hydrogen-bonding,
and vdW interactions, respectively. The E(I)pharma with
interaction type I (i.e., E, H, or V) is defined as
EI We pharma j j
j
K
() =
= ∑
1
2
where ej i st h ee n e r g yo b t a i n e db yt h eG E M D O C K
scoring function for the residue group j. Finally, iGEM-
DOCK provides the ranks of energy-based and pharma-
cological scoring functions for all screening compounds.
Implementation of iGEMDOCK
iGEMDOCK is an easy-to-use VS environment and
includes three main modules (Fig. 1): docking and vir-
tual screening tool (GEMDOCK); post-screening analy-
sis methods; and visualization tools (RasMol [22] and
Java Treeview [23]). We employed ERA as an example
to present these modules, procedures and features of
iGEMDOCK.
For protein-ligand docking/screening module, iGEM-
DOCK provides an interactive interface for the prepara-
tions of the binding site and compound library; setting
docking parameters; and monitoring progress status
(Fig. 1B). For most docking tools, users usually need to
prepare the binding site structure and compound library
through complicated steps (e.g., add hydrogen atoms
and generate the grids of the protein). Here, iGEM-
DOCK provides a straightforward method to derive the
binding site from the bounded ligand. For example, the
binding site of ERA (PDB code 1gwr) was obtained
from the estradiol (Fig. 1C). iGEMDOCK is able to
automatically consider the effects of hydrogen atoms
when preparing the binding site and the compound
library. In addition, iGEMDOCK allows users to visua-
lize and refine the binding site of the target protein.
Additionally, iGEMDOCK offers the similar way to pre-
pare screening compounds and docking parameters (e.g.,
the population size and the number of generations).
After the screening process, iGEMDOCK utilizes the
post-screening analysis module to infer pharmacological
interactions and cluster screening compounds based on
protein-ligand complexes and compound structures
( F i g .1 D ) .F i r s t ,iGEMDOCK generates interaction pro-
files and calculates the pharmacological preference (Wj)
of each interacting group for deriving the pharmacologi-
cal interactions (Fig. 2). These pharmacological prefer-
ences and interactions are shown in an interactive
window (Fig. 2G); furthermore, RasMol displays the
pharmacological interactions with conserved interacting
residues and functional groups of compounds (Fig. 2H).
Additionally, iGEMDOCK supports a hierarchical clus-
tering method to cluster screening compounds accord-
ing to interaction profiles and the atomic composition
(Fig. 1E). The atomic composition, which is similar to
the amino acid composition of a protein sequence, is
useful for measuring compound similarity. iGEMDOCK
provides an interactive interface for visualizing com-
pound similarity with a hierarchical tree by Java Tree-
view. Finally, iGEMDOCK ranks and visualizes the
screening compounds by combining the pharmacologi-
cal interactions and the energy-based scoring function.
Results and discussion
Pharmacological interactions
The pharmacological interactions derived by iGEM-
DOCK are often involved in biological reactions or
essential for ligand binding. We examined the pharma-
cological interactions on three selected target proteins
(ERA, ER, and TK). First, we compared the pharmacolo-
gical interactions, derived from 1000 screening com-
pounds, to the consensus interactions, derived from 10
active compounds (Table 1 and Fig. 3). Here, the residue
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Page 5 of 11i is considered as “hot spot” if the consensus interaction
ratio ≥0.5 [9,10,24,25]. Among 10 predicted pharmacolo-
gical interactions (residues) for ERA, 9 pharmacological
interactions (9 of 9 residues) agree with hot spots except
the L387 with the hydrogen-bonding interaction. For
TK, 8 of 14 pharmacological interactions (7 of 9 resi-
dues) are the hot spots. These results indicate the phar-
macological interactions (residues) from screening
compounds are often essential for the ligand binding.
For example, 10 active compounds of TK form stacking
interactions with the residue Y172 (vdW preference is
1.0 defined in Equation (1)) that stabilizes the binding of
thymine or purine moieties.
We also examined the pharmacological interactions by
their biological functions or binding mechanisms. For
estrogen receptor a, H524 (hydrogen-bonding prefer-
ences are 1.0 and 0.42 for ERA and ER, respectively) is
involved in a hydrogen-bonding network [26]; similarly,
E353 and R394 (hydrogen-bonding preferences ≥ 0.5 for
both ERA and ER) interact the structural water to form
the hydrogen bonding network (Table 1 and Fig. 3) [27].
These two hydrogen bonding networks are essential for
estrogen receptor modulators to trigger the responses of
estrogen receptor a[26,27]. For ER and ERA, hydropho-
bic interacting residues, L346, L387, F404, and L525
with high vdW interaction preferences, contact with the
sterols or flavones scaffolds of the active compounds.
These residues contribute the major vdW interactions
for the ligand binding of estrogen receptor a [28,29].
For TK, R222 and R163 play major roles for inhibitor
and substrate binding [30,31], and their hydrogen-bond-
ing preferences are 1.0 and 0.99, respectively (Table 1).
Our method identified the electrostatic interactions of
R222 and R163 (preferences are 1.0 and 0.4, respec-
tively), which help to transfer phosphate in the substrate
phosphorylation [30]. However, these two electrostatic
interactions are not observed from 10 active compounds
(Fig. 3). For the residue Q125 (H preference 0.40), the
TK activity was decreased over 90% if Q125 mutated
into Asp, Glu, or Asn [32]. The residues M128, Y172,
H 5 8 ,R 1 6 3 ,a n dY 8 8c o n s t i t u t eap o c k e tt of i xt h es u b -
strate, and their vdW preferences are 0.58, 1.00, 0.68,
Table 1 Pharmacological interactions and consensus interaction ratio on estrogen receptor a and thymidine kinase
Protein Predicted pharmacological
interactions
Consensus interaction
ratio
a
Related works
ERA R394-H
b (0.80
c) 1.0 Form hydrogen bonding networks for ligand binding [26,27]
E353-H (0.64) 0.8
H524-H (1.00) 1.0
L387-V (1.00) 0.9 Form non-polar contacts with A-ring of sterols scaffolds [28,29].
L387-H (0.52) 0.2
F404-V (0.90) 1.0
V346-V (0.98) 0.5
L391-V (0.61) 0.9
L384-V (0.57) 0.9
L525-H (0.53) 0.9
TK R222-H (1.00) 0.8 Transfer phosphate in the substrate phosphorylation [30,31,36]
R222-E (1.00) 0.0
R222-V (0.62) 0.4
R163-H (0.99) 0.6
R163-E (0.40) 0.0
R163-V (0.56) 0.8
E83-V (0.54) 0.2
Y101-H (0.40) 0.2 Form hydrogen bonds with thymidine; activity was decreased over 90% if
Q125 mutated [32]
Y101-V (0.45) 0.0
Q125-H (0.40) 1.0
Y172-V (1.00) 1.0 Sandwich the thymine moiety of substrates [33]
M128-V (0.58) 1.0
W88-V (0.87) 0.9 Constitute a pocket for ligand binding [33]
H58-V (0.68) 0.9
aThe consensus interaction ratio of the residue i is defined as Aj/A, where Aj is the number of active compounds interacting to the residue i and A is total
number of active compounds.
bH, E and V are the interaction types.
cThe pharmacological preferences (i.e. Wj defined in Equation (1)).
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Figure 3 Relationship between the pharmacological interactions and the active compounds of (A) ERA, (B) ER, and (C) TK. The residue
with a pharmacological preference ≥ 0.4 is colored by the interaction types [H: green (E353 and R394 in ERA); E: yellow; and V: gray (L391 and
F404 in ERA)]. In the profile, the first row presents the pharmacological preferences of the interacting residue groups using the color-coding bar,
with red-through-black indicating high-through-low. The following rows show the interactions between the active compounds and the
interacting residue groups. H, E, and V indicate the interaction types; M and S indicate the main chain and the side chain of the interacting
residue, respectively. The hydrogen-bonding or electrostatic interactions are colored in green if the energy ≤ -2.5. The vdW interactions are
colored in green when the energy is less than -4.
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Page 7 of 110.56, and 0.87, respectively (Table 1). For the substrate
binding, M128 and Y172 sandwich the thymine moiety
and W88 is a part of the quasi-helical motif [33,34].
These results demonstrated that the pharmacological
interactions derived by iGEMDOCK are often involved
in the biological functions and the ligand binding.
Molecular docking and virtual screening
To initially evaluate the utility of iGEMDOCK for dock-
ing and virtual screening, we selected a highly diverse
dataset with 305 protein-ligand complexes (i.e., CCDC/
Astex set [20] ) and ERA, ER, and TK with 1000 com-
pounds as test sets. Please note that the docking and
screening tool of iGEMDOCK is GEMDOCK which was
well-studied for VS and some applications [4,8,11-14].
In order to compare with previous works, we followed
the docking procedures and performance indices pro-
posed by Nissink, et al. A docked result was considered
as a success solution if the root-mean-square derivation
(RMSD) ≤2.0 Å between the docked solutions and X-ray
crystal structures. For these 305 complexes, the success
rates of iGEMDOCK and GOLD are 78% and 68%,
respectively (Table S1 in additional file 1).
The pharmacological scoring function was then
applied to identify the active compounds from the 1000
compounds of ERA, ER, and TK. Furthermore, we com-
pared the screening results with those of using the
energy-based scoring function of GEMDOCK. These
two approaches were tested on the same datasets. The
true hits of the three testing sets were used to access
the screening accuracy of the two approaches (Fig. S1 in
additional file 1). The screening accuracy was generally
improved when iGEMDOCK considered the pharmaco-
logical interactions.
We compared iGEMDOCK (pharmacological scoring
function) with three screening methods (DOCK, GOLD,
and FlexX) on the ER and TK sets (Table S2 in addi-
tional file 1). To compare with previous works, we fol-
lowed the experiment design and performance indices
used by Bissantz et al. W h e nt r u e - p o s i t i v er a t ei s8 0 % ,
the false positive rates were 2.3% (iGEMDOCK), 13.3%
(DOCK), 57.8% (FlexX), and 5.3% (GOLD), for ER. The
false positive rates were 7.8% (iGEMDOCK), 23.4%
(DOCK), 8.8% (FlexX), and 8.3% (GOLD) for TK.
Post-screening analysis
To identify leads from vast amount of docked poses
generated during the virtual screening procedure is the
key step for the drug discovery. In addition, the top-
ranked compounds based on the scoring functions are
not advisable since these compounds may be similar in
structures or physico-chemical properties. For these two
issues, iGEMDOCK provides a post-screening analysis
module to cluster compounds based on the interactions
profiles and the atomic compositions. Selecting repre-
sentative compounds from each cluster is able to main-
tain compound diversity and then reduces the false
positives. Further, when active compounds are available,
users can choose the similar compounds in the same
cluster of the actives based on hierarchical trees
(Fig. 1E). Notably, iGEMDOCK visualizes the interaction
profiles of the compounds, and thereby the top-ranked
compounds with pharmacological interactions can be
selected according to the interaction table (Fig. 2G).
The post-screening analysis module of iGEMDOCK is
useful for clustering and selecting compounds based on
interaction profiles. We selected a set of compounds,
including 10 ERA active compounds and top-ranked 100
compounds based on both the pharmacological and
energy-based scoring functions. The hierarchical cluster-
ing dendrogram and the profile revealed that the protein-
ligand interactions derived from the pharmacological
scoring function are significantly different from those
derived from the energy-based scoring function (Figs. 4A
and B). The compounds with the high pharmacological
scores and the active compounds consistently keep the
pharmacological interactions; conversely, the compounds
derived from the energy-based scoring function are often
lack of the pharmacological interactions (Fig. 4B). This
result indicates the pharmacological interactions are use-
ful for identifying active compounds. For example, the
t w oa c t i v ec o m p o u n d s ,E R A _ 0 3a n dE R A _ 0 6 ,w e r e
ranked as 187 and 160 using the energy-based scoring
function, respectively. When the pharmacological inter-
actions were considered, the ranks of ERA_03 and
ERA_06 were 91 and 87, respectively (Fig. 4C).
Some compounds having high pharmacological scores
are structurally and chemically similar to the active
compounds (Fig. 4C). For example, MFCD00003670
(Tetrahydrocortisol) and MFCD00012742 (Tetrahydro-
papaveroline) were analogues of the ERA active com-
pounds, and both of them were clustered into the same
cluster. In addition, the pharmacological scoring func-
tion can reduce the ill-effect of most energy-based scor-
ing functions which often favor high molecular weight
or highly-polar compounds [8,35]. For instance, the
ranks of two high molecular weight and polar com-
pounds, MFCD00009772 and MFCD00016940, are 267
and 274, respectively (Fig. 4C). To further examine the
pharmacological scoring function, we analyzed the rela-
tionship between the molecular weights of the active
compounds and the rank improvement using the phar-
macological scoring function (Fig. 5). The pharmacologi-
cal scoring function generally improves the screening
accuracy when the molecular weights of the active com-
pounds are less than 400.
In summary, iGEMDOCK can mine the pharmacolo-
gical interactions from the screening compounds
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Figure 4 Hierarchical clustering of iGEMDOCK for post screening analysis using ERA as the example. (A) Hierarchical clustering of the
interaction profile for the active compounds and top-ranked compounds selected by the pharmacological and energy-based scoring functions.
(B) The interaction profiles of the compounds belonging to the active compound cluster (blue block) and the compounds in the lowest energy cluster
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Figure 5 Relationship between the molecular weights of the active compounds and the rank improvement using the pharmacological scoring
function for ERA (●), ER (○), and TK (▲).
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Page 9 of 11without known active compounds. Therefore, iGEM-
DOCK can provide a good starting point for deriving
pharmacological interactions (residues) and identifying
new potential active compounds for a new protein
structure. In addition, iGEMDOCK offers the visualiza-
tion of the interaction profiles, pharmacological interac-
tions, and the hierarchical clustering dendrogram. Users
are able to easily observe and select compounds for
post-screening analysis to enrich accuracies.
Conclusions
We have developed a structure-based VS framework
iGEMDOCK from the preparations through to the post-
screening analysis. iGEMDOCK is an integrated and
easy-to-use environment which is especially useful for
post-screening analysis and inferring pharmacological
interactions from screening compounds. The friendly
user interface is helpful to biologically oriented nonex-
perts. The experimental results show that the pharmaco-
logical interactions are often essential for the binding of
the active compounds and involved in biological
mechanisms. The pharmacological interactions can
reduce the ill effects of energy-based scoring functions
to enrich the hit rates in VS. We believe iGEMDOCK is
useful for drug discovery and understanding protein-
ligand mechanisms.
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